Summary

• Doximity, Inc. delivered mixed FY26 results, with solid revenue growth but margin compression and a cautious near-term outlook.
• AI-driven engagement is accelerating, with rapid adoption of clinical tools and strong enterprise traction, but monetisation lags due to regulatory and operational friction.
• FY27 is positioned as a transition year, with guidance for just 4% revenue growth and EBITDA margin compression as AI investments ramp.
• DOCS' valuation now reflects a more mature SaaS profile, trading below historical multiples, as the market prices in execution and growth transition risks.

Thesis

Doximity, Inc. (DOCS) reported pretty mixed earnings this week. Non-GAAP EPS came in at $0.26, a figure that missed estimates by about $0.02, whilst revenue managed to reach $145.4 million, which was a 5.1% jump since last year and actually

1.39K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.